327 patients with cancer of the breast and involvement of axillary lymph nodes were randomised , after total mastectomy and axillary clearance , to receive either no additional treatment or oral cyclophosphamide 80 mg/m2 on days 1-14 , intravenous methotrexate 32 mg/m2 on days 1 and 8 , and intravenous fluorouracil 480 mg/m2 on days 1 and 8 ( cmf ) , which was repeated every 28 days for twelve cycles .
C0010583
cyclophosphamide
C0950521
cmf